Island Pharmaceuticals Ltd has released a press release.
Phase 2a PROTECT clinical trial dosed & Investor webinar
Filed with ASX ·
6ix hasn’t read this filing yet.
Island Pharmaceuticals Ltd on 6ix
Story so far
Earlier from Island Pharmaceuticals
- Binding LOI for proposed acquisition of Galidesivir
- ISLA-101 Phase 2a/b clinical trial progresses
- Non-binding term sheet signed with BioCryst
- Investor Presentation
- New data leads to proposed ISLA-101 Phase 2 efficiencies
Later from Island Pharmaceuticals
- Island completes $3.5m Placement
- Clinical trial progress update
- Receipt of R&D tax refund for FY2024
- ISLA-101 shows anti-dengue activity in Phase 2a readout
- US patent granted for ISLA-101
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals